These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 16650916)

  • 21. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using electronic mail to improve MMR uptake amongst third level students.
    Cooney F; Ryan A; Schinaia N; Breslin A
    Ir Med J; 2010 Mar; 103(3):72-4. PubMed ID: 20666068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mumps antibody levels among students before a mumps outbreak: in search of a correlate of immunity.
    Cortese MM; Barskey AE; Tegtmeier GE; Zhang C; Ngo L; Kyaw MH; Baughman AL; Menitove JE; Hickman CJ; Bellini WJ; Dayan GH; Hansen GR; Rubin S
    J Infect Dis; 2011 Nov; 204(9):1413-22. PubMed ID: 21933874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mumps outbreak among vaccinated university students associated with a large party, the Netherlands, 2010.
    Greenland K; Whelan J; Fanoy E; Borgert M; Hulshof K; Yap KB; Swaan C; Donker T; van Binnendijk R; de Melker H; Hahné S
    Vaccine; 2012 Jun; 30(31):4676-80. PubMed ID: 22579874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tracking mothers' attitudes to MMR immunisation 1996-2006.
    Smith A; Yarwood J; Salisbury DM
    Vaccine; 2007 May; 25(20):3996-4002. PubMed ID: 17395344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term persistence of antibodies after one or two doses of MMR-vaccine.
    Vandermeulen C; Mathieu R; Geert LR; Pierre VD; Karel H
    Vaccine; 2007 Sep; 25(37-38):6672-6. PubMed ID: 17692439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-preventable mumps outbreaks in schoolchildren in Catalonia.
    Cardeñosa N; Domínguez A; Camps N; Martínez A; Torner N; Navas E; Salleras L
    Scand J Infect Dis; 2006; 38(8):671-4. PubMed ID: 16857613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developing audit standards required for outbreaks of communicable diseases-lessons from a mumps outbreak.
    Kipping RR; Hamilton S; Roderick M; Alexander K
    J Public Health (Oxf); 2006 Dec; 28(4):347-50. PubMed ID: 17065178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outbreak of mumps in a school setting, United Kingdom, 2013.
    Aasheim ET; Inns T; Trindall A; Emmett L; Brown KE; Williams CJ; Reacher M
    Hum Vaccin Immunother; 2014; 10(8):2446-9. PubMed ID: 25424953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MMR vaccination: answers to some parents' questions.
    Moreton J
    J Fam Health Care; 2002; 12(6):151-3. PubMed ID: 12630143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measles, rubella, mumps, and varicella seroprevalence among health care workers in Turkey: is prevaccination screening cost-effective?
    Celikbas A; Ergonul O; Aksaray S; Tuygun N; Esener H; Tanir G; Eren S; Baykam N; Guvener E; Dokuzoguz B
    Am J Infect Control; 2006 Nov; 34(9):583-7. PubMed ID: 17097453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measles, mumps and rubella infections and atopic disorders in MMR-unvaccinated and MMR-vaccinated children.
    Bernsen RM; van der Wouden JC
    Pediatr Allergy Immunol; 2008 Sep; 19(6):544-51. PubMed ID: 18266826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrent outbreaks of mumps in Lothian and the impact of waning immunity.
    Waugh CJ; Willocks LJ; Templeton K; Stevenson J
    Epidemiol Infect; 2020 Jun; 148():e131. PubMed ID: 32616093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
    Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
    East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.
    Davidkin I; Jokinen S; Broman M; Leinikki P; Peltola H
    J Infect Dis; 2008 Apr; 197(7):950-6. PubMed ID: 18419470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mumps outbreaks in four universities in the North West of England: prevention, detection and response.
    Kay D; Roche M; Atkinson J; Lamden K; Vivancos R
    Vaccine; 2011 May; 29(22):3883-7. PubMed ID: 21447315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mumps resurgences in the United States: A historical perspective on unexpected elements.
    Barskey AE; Glasser JW; LeBaron CW
    Vaccine; 2009 Oct; 27(44):6186-95. PubMed ID: 19815120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom.
    Miller E; Andrews N; Stowe J; Grant A; Waight P; Taylor B
    Am J Epidemiol; 2007 Mar; 165(6):704-9. PubMed ID: 17204517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.